Replimune: Audience

Replimune is pioneering the development of a novel class of tumor-directed oncolytic immunotherapies designed to deliver transformational results for difficult-to-treat cancers. Their mission is to revolutionize cancer treatment by activating a powerful and durable full-body anti-tumor response.